CLDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Celldex Therapeutics Inc (CLDX) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the stock has potential catalysts in 2026 and some positive analyst sentiment, the recent price drop, lack of immediate positive news, and weak financial performance make it prudent to hold off on investing right now.
The stock shows mixed technical signals. The MACD is positive but contracting, RSI is neutral, and moving averages are bullish. However, the stock closed at $29.88, below the pivot level of $30.202, indicating potential weakness. Key support is at $28.899.
Analysts have raised price targets, with some projecting significant upside. The company is entering a catalyst-rich period with multiple Phase 3 and Phase 2 programs, and key data readouts expected in 2026.
The stock dropped 4.32% in regular trading and 0.74% in pre-market. Financial performance in Q4 2025 was weak, with revenue dropping significantly (-89.70% YoY). No recent news or significant trading trends from hedge funds or insiders. Congress trading data is also absent.
In Q4 2025, revenue dropped by 89.70% YoY to $121,000, indicating significant weakness in operational performance. However, net income and EPS improved YoY, though they remain negative, reflecting ongoing losses.
Analysts are generally positive, with multiple firms raising price targets recently. Stifel has a Buy rating with a target of $68, Morgan Stanley has an Overweight rating with a target of $44, and Goldman Sachs has a Neutral rating with a target of $34.
